Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.
How pharmacists can use shared decision-making to improve antibiotic use.
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.
Will this winter bring the feared twindemic of SARS-CoV-2 and influenza, or will another common infection reemerge?
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Similar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
Implications for antimicrobial use and antimicrobial resistance.
Here is a look at some of the treatment alternatives, which can offer simpler logistics and cost considerations.
Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.
This agent is likely best utilized as part of a combination when treating this bacterium but data regarding appropriate combinations are scarce.
This crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.
A preview of our August 2021 issue Chairman’s Letter.
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
Both undertreatment and overtreatment were common in this cohort of penicillin-allergic pregnant women with Group B Streptococcus (GBS).
Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.
Changes in microbiology and antimicrobial resistance patterns warrant reevaluation of our current therapies for this condition.
Clinical and public health laboratories reported increased influenza virus detections over the past few weeks, but US cases remains comparatively low to previous flu seasons.
This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.
The limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.